AstraZeneca Annual Report and Financial Statements 74 Form 20-F Information 2003 Notes to the Financial Statements continued 6 Dividends to shareholders 2003 2002 2001 2003 2002 2001 Per Per Per share share share $m $m $m Interim, paid on 6 October 2003 $0.255 $0.23 $0.23 436 398 405 Second interim, to be confirmed as final, payable 6 April 2004 $0.540 $0.47 $0.47 914 808 820 $0.795 $0.70 $0.70 1,350 1,206 1,225 7 Earnings per $0.25 Ordinary Share 2003 2002 2001 Net profit for the financial year before exceptional items $m 3,036 3,186 3,044 Exceptional items after tax $m see Note 3 350 138 Net profit for the financial year $m 3,036 2,836 2,906 Earnings per Ordinary Share before exceptional items $1.78 $1.84 $1.73 Loss per Ordinary Share on exceptional items $0.20 $0.08 Earnings per Ordinary Share $1.78 $1.64 $1.65 Diluted earnings per Ordinary Share before exceptional items $1.78 $1.84 $1.73 Diluted loss per Ordinary Share on exceptional items $0.20 $0.08 Diluted earnings per Ordinary Share $1.78 $1.64 $1.65 Weighted average number of Ordinary Shares in issue for basic earnings millions 1,709 1,733 1,758 Dilutive impact of share options outstanding millions 3 23 Diluted average number of Ordinary Shares in issue millions 1,712 1,735 1,761 There are no options, warrants or rights outstanding in respect of unissued shares except for employee share option schemes.
The number of options outstanding and the weighted average exercise price of these options is shown in Note 30.
The earnings figures used in the calculations above are unchanged for diluted earnings per Ordinary Share.
Earnings per Ordinary Share before exceptional items have been calculated to eliminate the impact of exceptional items on the results of the business.
